Key result
Early dabigatran in minor stroke without AFib shows safety with 0 symptomatic hemorrhagic transformations.
Why the study?
Is dabigatran safe and feasible when initiated within 24 hours of onset in patients with minor acute ischemic stroke without atrial fibrillation?
Cohort (n=53)
Is dabigatran safe and feasible when initiated within 24 hours of onset in patients with minor acute ischemic stroke without atrial fibrillation?
Initiating dabigatran within 24 hours of a minor acute ischemic stroke in patients without atrial fibrillation appears feasible and safe, with no symptomatic hemorrhagic transformation observed in this small cohort.
No takes yet. Share an insight, caveat, or question.
Early dabigatran may be feasible post-minor stroke without AF; hypothesis-generating and should not yet change practice.
Kate et al. (2015) conducted a cohort in Acute ischemic stroke without atrial fibrillation (n=53). Dabigatran was evaluated on Symptomatic hemorrhagic transformation. Initiating dabigatran within 24 hours of minor stroke in patients without atrial fibrillation was safe, with 0 of 53 patients experiencing symptomatic hemorrhagic transformation at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: